Illumina 'Confident' in Array Market Outlook Despite 3 Percent Dip in Q3 Chip Sales | GenomeWeb

A drop in demand for Illumina's array instruments, coupled with a market preference for lower complexity, and therefore lower priced, chips, caused the San Diego vendor's array revenues to decline by 3 percent in the third quarter, Illumina executives said this week.

At the same time, the company's management said it is "committed" to the array market and provided a positive forecast for the business, citing "substantial demand" in the quarter for its genotyping services and orders for its Infinium products that already have already exceeded total 2012 orders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.